ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3.

ABSTRACT: Breast carcinoma (BC) is the most common malignant neoplasm occurring in women, posing a serious threat to public health. Metastasis is its leading cause of death, nevertheless there is still a lack of effective treatment. Epithelial-mesenchymal transition (EMT) is a critical process involved in cancer malignant progression, which is expected to provide new insights into BC treatment. Through lasso regression SVM-RFE algorithms, ASCL2 was identified as a potential regulator for BC progression. Multi-omics bioinformatics investigation confirmed its great value in clinical assessments. ASLC2 can elevate the decision-making benefit of TNM and AJCC-stage prognostic models and distinguish the prognostic differences of patients with different molecular subtypes. A survival meta-analysis confirme

SUBMITTER: Yin Y 

PROVIDER: S-EPMC12770503 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature